Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Genenta Science S.p.A. Unsponsored ADR GNTA

Healthcare  —  Biotechnology
0.69 0.02 2.99% as of 25 Sep
Market cap
$32.4M
P/E
—
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Genenta Science S.p.A. Unsponsored ADR (GNTA) Business Profile

Updated before January 2025

Company Overview

Genenta Science S.p.A. Unsponsored ADR (GNTA) is a biotechnology company specializing in the development of innovative gene-based therapies for the treatment of cancer. Founded in 2014, the company is headquartered in Milan, Italy, and has established itself as a pioneer in the field of immuno-gene therapy. Genenta was co-founded by Pierluigi Paracchi, who also serves as the CEO, and Luigi Naldini, a globally recognized scientist in the field of gene therapy. The company’s leadership team includes a mix of experienced executives and scientific experts, ensuring a strong foundation for innovation and growth.

Genenta Science operates with a mission to harness the power of gene therapy to address unmet medical needs in oncology. The company’s proprietary platform, Temferon™, is designed to deliver therapeutic genes to the tumor microenvironment, enhancing the immune system’s ability to combat cancer. Over the years, Genenta has gained recognition for its cutting-edge research and has secured partnerships with leading academic institutions and industry players.

Core Business Segments

Genenta Science focuses on the development of gene-based therapies, with its primary emphasis on oncology. The company’s core business segments include:

1. Immuno-Gene Therapy

  • Temferon™ Platform: Genenta’s flagship product, Temferon™, is an innovative gene therapy platform that utilizes hematopoietic stem cells (HSCs) to deliver therapeutic genes to the tumor microenvironment. This approach aims to modulate the immune response and inhibit tumor growth.
  • Pipeline Products: Genenta is actively developing a pipeline of therapies targeting various types of cancers, including glioblastoma, multiple myeloma, and other solid tumors. These therapies are in different stages of preclinical and clinical development.

2. Research and Development Services

  • Genenta collaborates with academic institutions and pharmaceutical companies to advance the understanding of gene therapy and its applications in oncology. The company provides research and development services, leveraging its expertise in gene editing, vector design, and preclinical studies.

Business Model

Genenta Science operates on a business model that integrates cutting-edge research, clinical development, and strategic partnerships to generate revenue. The company’s primary revenue streams include:

  • Product Development: Genenta invests heavily in the development of its proprietary therapies, with the goal of commercializing these products upon regulatory approval.
  • Collaborations and Licensing: The company partners with academic institutions and pharmaceutical companies to co-develop therapies and license its proprietary technologies.
  • Grants and Funding: Genenta secures funding from government grants, private investors, and venture capital firms to support its research and development activities.

By focusing on innovation and collaboration, Genenta aims to bring transformative therapies to market while maintaining a sustainable business model.

Strategic Direction

Genenta Science is committed to advancing its pipeline of gene-based therapies and expanding its presence in the global oncology market. The company’s strategic priorities include:

  • Pipeline Expansion: Genenta plans to accelerate the development of its existing pipeline and explore new indications for its therapies. The company is also investing in next-generation gene editing technologies to enhance the efficacy and safety of its products.
  • Global Market Penetration: Genenta aims to establish a strong presence in key markets, including the United States, Europe, and Asia. The company is actively seeking regulatory approvals and commercial partnerships to facilitate market entry.
  • Sustainability Goals: Genenta is committed to conducting its operations in an environmentally and socially responsible manner. The company is exploring sustainable manufacturing practices and aims to minimize its environmental footprint.
  • Innovation and Collaboration: Genenta continues to collaborate with leading academic institutions and industry players to stay at the forefront of gene therapy research. The company is also exploring opportunities to expand its technology platform into other therapeutic areas.

Competitive Landscape

Genenta Science operates in a highly competitive biotechnology sector, with several companies developing gene-based therapies for cancer. Key competitors include:

  • Bluebird Bio: A leader in gene therapy, Bluebird Bio focuses on developing treatments for severe genetic diseases and cancer.
  • Adaptimmune Therapeutics: Specializes in T-cell therapies for cancer, with a strong pipeline of products targeting solid tumors.
  • Kite Pharma (a Gilead Company): A pioneer in CAR-T cell therapy, Kite Pharma develops innovative treatments for hematologic malignancies.
  • Sangamo Therapeutics: Focuses on gene editing and gene therapy for a range of diseases, including cancer.

Despite the competition, Genenta differentiates itself through its proprietary Temferon™ platform and its focus on the tumor microenvironment.

Risk Factors

Like any biotechnology company, Genenta Science faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The development and approval of gene therapies are subject to stringent regulatory requirements, which can delay product launches.
  • Market Dependence: Genenta’s success is heavily dependent on the commercial viability of its therapies. Failure to achieve market acceptance could impact revenue.
  • Supply Chain Disruptions: The company relies on a complex supply chain for the production of its therapies. Disruptions in the supply chain could delay clinical trials and product launches.
  • Competition: The biotechnology sector is highly competitive, with numerous companies developing similar therapies. Genenta must continuously innovate to maintain its competitive edge.
  • Financial Risks: As a pre-revenue company, Genenta relies on external funding to finance its operations. Any challenges in securing funding could impact its ability to execute its business plan.

Recent Developments

Genenta Science has made significant progress in recent years, including:

  • Clinical Trials: The company has advanced its lead product, Temferon™, into clinical trials for glioblastoma and multiple myeloma. Early results have shown promising safety and efficacy profiles.
  • Partnerships: Genenta has entered into strategic collaborations with leading academic institutions and pharmaceutical companies to accelerate the development of its therapies.
  • Technological Innovations: The company has made advancements in its gene editing and vector design technologies, enhancing the precision and efficiency of its therapies.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of biotechnology in addressing global health challenges. Genenta has leveraged this momentum to strengthen its position in the market.

Investment Considerations

Investors considering Genenta Science should weigh the following strengths and risks:

Strengths

  • Innovative Platform: Genenta’s Temferon™ platform offers a unique approach to cancer treatment, targeting the tumor microenvironment.
  • Strong Leadership: The company’s experienced leadership team and scientific advisors provide a solid foundation for growth.
  • Growing Pipeline: Genenta has a robust pipeline of therapies targeting multiple cancer indications.
  • Strategic Partnerships: Collaborations with academic institutions and industry players enhance the company’s research capabilities and market reach.

Risks

  • Regulatory Uncertainty: The approval process for gene therapies is complex and time-consuming.
  • Financial Dependence: As a pre-revenue company, Genenta relies on external funding to finance its operations.
  • Market Competition: The biotechnology sector is highly competitive, with numerous companies developing similar therapies.
  • Clinical Risks: The success of Genenta’s therapies depends on the outcomes of clinical trials, which are inherently uncertain.

Conclusion

Genenta Science S.p.A. is a promising player in the biotechnology sector, with a strong focus on gene-based therapies for cancer. The company’s innovative Temferon™ platform, robust pipeline, and strategic partnerships position it for long-term growth. While the company faces challenges such as regulatory hurdles and market competition, its commitment to innovation and collaboration provides a solid foundation for success. As Genenta continues to advance its pipeline and expand its global presence, it is well-positioned to make a significant impact in the field of oncology.